October 28, 2022
Minaris Regenerative Medicine GmbH and Mendus AB extend manufacturing partnership to large-scale production of DCP-001, an experimental allogeneic cell-based immunotherapy addressing tumor recurrence
Munich, Germany, and Stockholm, Sweden - Oct 28, 2022. Mendus AB (“Mendus publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence and Minaris Regenerative Medicine GmbH („Minaris“), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have extended their manufacturing partnership for technology ...
